BNTX
BioNTech SE
Nasdaq: BNTX · Mainz, 2M · Healthcare
Market Cap$28.22B
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range—
Avg Volume—3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$111.60+26.8%
Pipeline
Drug candidates sponsored by BioNTech SE · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | BNT162b2 | SARS-CoV-2 Infection+6 more | Completed | 2023-08-16past | 9 | |
| Phase 2 | BNT162b1 | SARS-CoV-2 Infection+2 more | Completed | 2023-02-10past | 2 | |
| Phase 2 | Biological/Vaccine: BNT162b2 10mcg | SARS-CoV-2 Infection, COVID-19 | Completed | 2023-10-04past | 1 | |
| Phase 2 | BNT162b5 Bivalent (WT/OMI BA.2) | SARS-CoV-2 Infection+1 more | Completed | 2024-03-26past | 1 | |
| Phase 3 | Influenza and COVID-19 Combination A | Influenza+1 more | Completed | 2024-11-26past | 1 | |
| Phase 2 | BNT162b2 (Omi XBB.1.5) | SARS-CoV-2 Infection+1 more | Completed | 2025-03-13past | 1 | |
| Phase 3 | BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) | COVID-19+1 more | Active, not recruiting | 2026-05-05 | 1 | |
| Phase 3 | Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose | SARS-CoV-2 Virus+2 more | Active, not recruiting | 2026-07-13 | 2 | |
| Phase 3 | BNT162b2 Vaccine | COVID-19+1 more | Active, not recruiting | 2026-07-31 | 1 | |
| Phase 3 | BNT162b2 (2025/2026 formulation) | COVID-19+1 more | Active, not recruiting | 2026-07-31 | 1 | |
| Phase 3 | BNT324 | Metastatic Castration-resistant Prostate Cancer+1 more | Recruiting | 2027-08 | 2 | |
| Phase 3 | Pumitamig | Extensive-stage Small-cell Lung Cancer+4 more | Recruiting | 2027-12 | 6 | |
| Phase 3 | BNT323/DB-1303 | Endometrial Cancer | Recruiting | 2028-03 | 1 | |
| Phase 2 | BNT113 | Unresectable Head and Neck Squamous Cell Carcinoma+2 more | Recruiting | 2029-04 | 1 | |
| Phase 1 | BNT162b3 | Covid-19+1 more | Completed | 2021-03-12past | 1 | |
| Phase 1 | BNT162a1 | Infections, Respiratory+5 more | Completed | 2021-06-30past | 1 | |
| Phase 2 | BNT162b2s01 | COVID-19+1 more | Completed | 2022-04-14past | 1 | |
| Phase 1 | BNT141 | Solid Tumor+7 more | Terminated | 2023-07-24past | 1 | |
| Phase 2 | bivalent BNT162b2 (original/Omi BA.4/BA.5) | Influenza, Human+1 more | Completed | 2023-12-28past | 1 | |
| Phase 1 | BNT411 | Solid Tumor+1 more | Terminated | 2024-01-19past | 1 | |
| Phase 1 | BNT112 | Prostate Cancer | Terminated | 2024-01-23past | 1 | |
| Phase 2 | BNT111 | Melanoma Stage III+2 more | Completed | 2024-01-25past | 1 | |
| Phase 1 | BNT151 | Solid Tumor | Terminated | 2024-05-28past | 1 | |
| Phase 1 | BNT321 0.5 mg/kg | Pancreatic Cancer | Terminated | 2024-09-18past | 1 | |
| Phase 1 | BNT165e | Malaria | Completed | 2025-05-28past | 1 | |
| Phase 1 | Investigational Influenza Vaccine | Influenza,Human+3 more | Completed | 2025-12-17past | 2 | |
| Phase 1 | BNT142 | Solid Tumor | Terminated | 2025-12-22past | 1 | |
| Phase 1 | BNT164a1 | Tuberculosis | Active, not recruiting | 2026-03-12past | 2 | |
| Phase 2 | RO7198457 intravenous (IV) | Colorectal Cancer Stage II+1 more | Recruiting | 2026-11 | 1 | |
| Phase 1 | BNT166a | Monkeypox+3 more | Recruiting | 2027-06 | 2 | |
| Phase 2 | BNT327 Dose Level 1 (DL1) | Extensive-stage Small-cell Lung Cancer+4 more | Active, not recruiting | 2027-06 | 2 | |
| Phase 1 | BNT314 | Metastatic Colorectal Cancer+1 more | Recruiting | 2027-06 | 2 | |
| Phase 1 | BNT3212 | Advanced Solid Tumor | Recruiting | 2027-11 | 1 | |
| Phase 1 | BNT326 | Advanced Solid Tumor+1 more | Recruiting | 2028-02 | 2 | |
| Phase 1 | BNT323 | Locally Advanced Breast Cancer+2 more | Recruiting | 2028-05 | 1 | |
| Phase 1 | BNT329 | Advanced Solid Cancers | Recruiting | 2030-05 | 1 | |
| Phase 1 | BNT3214 | Advanced Solid Tumor Cancer | Recruiting | 2030-10 | 1 | |
| Phase 2 | CLDN6 CAR-T | Testicular Germ Cell Tumor+1 more | Withdrawn | 2042-06 | 1 | |
| Phase 1 | IVAC_W_bre1_uID | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | Completed | 2020-05-13past | 1 | |
| Phase 1 | Lipo-MERIT | Melanoma | Completed | 2023-06-20past | 1 | |
| Phase 1 | BNT165b1 | Malaria | Completed | 2024-02-23past | 1 | |
| Phase 1 | BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg | SARS-CoV-2 Infection+1 more | Completed | 2024-11-22past | 1 | |
| Phase 1 | BNT331 | Bacterial Vaginosis | Completed | 2025-07-31past | 1 | |
| Phase 1 | BNT152 | Solid Tumor | Completed | 2025-09-10past | 1 | |
| Phase 1 | BNT163 | Genital Herpes Simplex Type 2 | Active, not recruiting | 2026-10 | 1 | |
| Phase 1 | BNT351 | HIV -1 Infection | Recruiting | 2027-06 | 1 | |
| Phase 1 | BNT317 DL1 | Advanced Solid Tumor | Recruiting | 2028-06 | 1 | |
| Phase 1 | BNT116 | Non-Small Cell Lung Cancer | Recruiting | 2030-02 | 1 | |
| N/A | Unnamed | Colorectal Cancer Stage II+1 more | Active, not recruiting | 2025-04-23past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
mRNA platforms · 2 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.